T cells have been implicated in the pathogenesis of
acute kidney injury (AKI) and its progression to
chronic kidney disease (CKD). Previous studies suggest that Th17 cells participate during the AKI-to-CKD transition, and inhibition of T cell activity by
mycophenolate mofetil (MMF) or
losartan attenuates the development of
fibrosis following AKI. We hypothesized that T cell-deficient rats may have reduced levels of
IL-17 cytokine leading to decreased
fibrosis following AKI. Renal ischemis-reperfusion (I/R) was performed on T cell-deficient athymic rats (Foxn1rnu-/rnu-) and control euthymic rats (Foxn1rnu-/+), and CKD progression was hastened by unilateral
nephrectomy at day 33 and subsequent exposure to 4.0%
sodium diet. Renal
fibrosis developed in euthymic rats and was reduced by MMF treatment. Athymic rats exhibited a similar degree of
fibrosis, but this was unaffected by MMF treatment. FACS analysis demonstrated that the number of IL-17+ cells was similar between postischemic athymic vs. euthymic rats. The source of
IL-17 production in euthymic rats was predominately from conventional T cells (CD3+/CD161-). In the absence of conventional T cells in athymic rats, a compensatory pathway involving natural killer cells (CD3-/CD161+) was the primary source of
IL-17. Blockade of
IL-17 activity using IL-17Rc receptor significantly decreased
fibrosis and neutrophil recruitment in both euthymic and athymic rats compared with vehicle-treated controls. Taken together, these data suggest that
IL-17 secretion participates in the pathogenesis of AKI-induced
fibrosis possibly via the recruitment of neutrophils and that the source of
IL-17 may be from either conventional T cells or NK cells.